<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04379973</url>
  </required_header>
  <id_info>
    <org_study_id>HYOIL</org_study_id>
    <nct_id>NCT04379973</nct_id>
  </id_info>
  <brief_title>Live Birth After Additional Tubal Flushing With Oil-based Contrast Versus no Additional Flushing:</brief_title>
  <acronym>HYFOIL</acronym>
  <official_title>Live Birth After Additional Tubal Flushing With Oil-based Contrast Versus no Additional Flushing: a Randomised, Multicentre, Parallel Group Pragmatic Trial in Infertile Women With at Least One Patent Tube at Hysterosalpingo-foam Sonography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dafne Balemans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ten to 15 percent of couples in their reproductive lifetime face fertility problems which is&#xD;
      defined by WHO as the absence of pregnancy after minimal 12 months of unprotected sexual&#xD;
      intercourse. The three most frequent causes of subfertility are: sperm defects, ovulation&#xD;
      disorders and tubal pathology. In order to exclude tubal pathology, tubal patency tests are&#xD;
      performed under ultrasound guidance with foam (hysterosalpingo-foam sonography (Hyfosy)) or&#xD;
      with contrast/water (hysterosalpingo-contrast sonography (Hycosy)).&#xD;
&#xD;
      This trial will investigate whether tubal flushing with an oil-soluble contrast medium (OSCM)&#xD;
      can increase the likelihood of a spontaneous conception after tubal patency testing with&#xD;
      Hyfosy under ultrasound guidance compared to no additional flushing in a population of&#xD;
      infertile women between 18 and 40 years of age with absence of pregnancy after 12 months of&#xD;
      unprotected sexual intercourse or who have three cycles of donor insemination without&#xD;
      pregnancy or three ovulatory ovulation induction cycles without pregnancy. The use of&#xD;
      Lipiodol Ultra Fluide® is off-label in Hyfosy.&#xD;
&#xD;
      This multicenter, randomised, open-label, comparative and pragmatic trial compares 2 arms&#xD;
      which will be randomised 1:1:&#xD;
&#xD;
        -  Intervention group: Tubal flush with 5-10mL oil-soluble contrast medium (Lipiodol Ultra&#xD;
           Fluide®, Guerbet, France) immediately after Hyfosy&#xD;
&#xD;
        -  Control group: No additional intervention after Hyfosy The study comprises a screening&#xD;
           period of maximum 8 weeks (w-8 to d1), randomisation (w-8 to d1), a start study visit at&#xD;
           which the Hyfosy is performed (d1) and a fertility treatment period of 6 months&#xD;
           (d1-w26). If the woman is not pregnant at 6 months after Hyfosy, the follow-up will last&#xD;
           till 12 months (w52). If the participant is pregnant at 6 months after Hyfosy, the&#xD;
           follow-up will last till maximal 4 months after live birth or miscarriage.&#xD;
&#xD;
      The primary endpoint is the occurrence of live birth, with the first day of the last&#xD;
      menstrual cycle in which the patient conceives within 6 months after Hyfosy. Secondary&#xD;
      endpoints consist of reproductive outcomes, gestational age at delivery, birth weight,&#xD;
      neonatal mortality, major congenital anomaly, neonatal outcomes and thyroid function,&#xD;
      pregnancy complications, number of complications during or immediately after the&#xD;
      intervention, pain score of the Hyfosy and additional flush, thyroid function of the mother,&#xD;
      general and disease-specific quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth</measure>
    <time_frame>Delivery</time_frame>
    <description>the occurrence of live birth, counting from the first day of the last menstrual cycle in which the patient conceives within 6 months after Hyfosy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of pregnancy</measure>
    <time_frame>15 months after Hyfosy</time_frame>
    <description>single or multiple pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of miscarriages</measure>
    <time_frame>15 months after Hyfosy</time_frame>
    <description>presence of miscarriages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of pregnancy complications</measure>
    <time_frame>15 months after Hyfosy</time_frame>
    <description>gestational diabetes, hypertensive disease, placenta praevia, intrauterin growth restriction, premature birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ectopic pregnancies</measure>
    <time_frame>15 months after Hyfosy</time_frame>
    <description>the presence of ectopic pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinical pregnancies</measure>
    <time_frame>15 months after Hyfosy</time_frame>
    <description>the presence of clinical pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication during or after Hyfosy with intervention</measure>
    <time_frame>immediately after intervention</time_frame>
    <description>embolism, anaphylactic shock, pelvic inflammatory disease, intravasation, infection and hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score of the Hyfosy with or without intervention</measure>
    <time_frame>immediately after Hyfosy</time_frame>
    <description>VAS (0 = no pain; 10 = worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score of the intervention with IMP if applicable</measure>
    <time_frame>immediately after intervention</time_frame>
    <description>VAS (0 = no pain; 10 = worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid function of baby</measure>
    <time_frame>3 days after delivery</time_frame>
    <description>heel prick test (TSH, FT4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birthweight</measure>
    <time_frame>at delivery</time_frame>
    <description>Birthweight of baby</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>at delivery</time_frame>
    <description>Live birth after how many weeks pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal care</measure>
    <time_frame>at delivery</time_frame>
    <description>Neonatal care (Yes/No)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of babies</measure>
    <time_frame>at delivery</time_frame>
    <description>Number of babies after live birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal thyroid function</measure>
    <time_frame>4 weeks, 26 weeks, 15 weeks after delivery</time_frame>
    <description>TSH, FT4 determination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General quality of life</measure>
    <time_frame>26 weeks</time_frame>
    <description>EuroQol-5D-5Levels (EQ-5D-5L):&#xD;
Level 1: indicating no problem Level 2: indicating slightproblems Level 3: indicating moderateproblems Level 4: indicating severe problems Level 5:indicating extreme problems; VAS (score 0 = worst health status; score 100 = best health status) How higher the score, how better the quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific quality of life</measure>
    <time_frame>26 weeks</time_frame>
    <description>Fertility Quality Of Life tool (FertiQol):&#xD;
Very poor (0), poor (1), neither poor nor good (2), very good (4)&#xD;
Very dissatisfied (0), dissatisfied (1), neither satisfied nor dissatisfied (2), satisfied (3), very satisfied (4)&#xD;
Always (0), very often (1), quite often (2), Seldom (3), never (4)&#xD;
An extreme amount (0), very much (1), a moderate amount (2), a little (3), not at all (4)&#xD;
Completely (0), a great deal (1), moderately (2), not much (3), not at all (4)&#xD;
Scores on the response scales are reversed, summed and scaled to range from 0 to 100. Higher scores on the subscales and total scores indicate better quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Mortality</measure>
    <time_frame>at delivery</time_frame>
    <description>Neonatal death after delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Congenital Anomaly</measure>
    <time_frame>at delivery</time_frame>
    <description>Neonatal major anomaly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gender of baby</measure>
    <time_frame>at delivery</time_frame>
    <description>Gender of baby (M/F)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">736</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Tubal flush with Lipiodol Ultra Fluide® after Hyfosy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No tubal flush after Hyfosy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipiodol Ultra Fluide®</intervention_name>
    <description>Tubal flush with 5-10mL oil-soluble contrast medium (OSCM) (Lipiodol Ultra Fluide®, Guerbet, France) immediately after Hyfosy. The use will be off-label.</description>
    <arm_group_label>Tubal flush with Lipiodol Ultra Fluide® after Hyfosy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Infertile women undergoing Hyfosy as part of the fertility workup. Women will be eligible&#xD;
        if they&#xD;
&#xD;
          -  are ≥ 18 years and &lt; 40 years&#xD;
&#xD;
          -  have infertility defined as&#xD;
&#xD;
               -  lack of conception despite 12 months of unprotected intercourse OR;&#xD;
&#xD;
               -  if they are taking part in a donor sperm insemination programme: three cycles of&#xD;
                  donor insemination without pregnancy OR;&#xD;
&#xD;
               -  in case of treated ovulation disorder: three ovulatory ovulation induction cycles&#xD;
                  without pregnancy&#xD;
&#xD;
          -  have tubal patency of at least one Fallopian tube on Hyfosy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Women with&#xD;
&#xD;
          -  known iodine allergy&#xD;
&#xD;
          -  allergy to poppy seed oil&#xD;
&#xD;
          -  ovulation disorders defined as less than eight menstrual cycles per year who did not&#xD;
             have three ovulatory cycles after ovulation induction&#xD;
&#xD;
          -  contra-indication to have tubal patency testing according to the site's indication&#xD;
&#xD;
          -  active thyroid disorders&#xD;
&#xD;
          -  untreated subclinical hypothyroidism (TSH&gt;2.5mIU/L) in case of auto-immune thyroid&#xD;
             disease&#xD;
&#xD;
          -  uterine surgery in the past two months before Hyfosy&#xD;
&#xD;
          -  a male partner (if applicable) with a post-wash Total Motile Sperm Count (TMC) &lt; 1x106&#xD;
             and/or TMC &lt; 3x106 in the native sperm analysis [TMC is defined as volume X&#xD;
             concentration X (A (progressive) + B (non progressive) motility in %) divided by 100]&#xD;
&#xD;
          -  an indication for IVF defined as patients who are advised to go to IVF immediately&#xD;
             because of bilateral tubal block, severe male factor infertility, unsolved anovulatory&#xD;
             problems, endometriosis with residual functional problems&quot;&#xD;
&#xD;
          -  no Belgian national number (RRN/INS)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Diane De Neubourg</last_name>
    <phone>+32 3 821 45 98</phone>
    <email>diane.deneubourg@uza.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane De Neubourg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imelda</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Pelckmans</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arne Van De Vijver</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHIREC</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romain Imbert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCL Saint Luc</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Wyns</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Blockeel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost Limburg</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie Dhont</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominic Stoop</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Lennik</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Delbaere</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharon Lie Fong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHC Mont Légia</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Goffioul</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Larie Henry</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Dafne Balemans</investigator_full_name>
    <investigator_title>Clinical Trial Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
    <mesh_term>Flushing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

